Network Signatures of Survival in Glioblastoma Multiforme

PLoS Computational Biology

Volumn 9, Issue 9, 2013, Pages

  Patel, Vishal N ^a   Gokulrangan, Giridharan ^a   Chowdhury, Salim A ^b   Chen, Yanwen ^c   Sloan, Andrew E ^d   Koyutürk, Mehmet ^a,e   Barnholtz Sloan, Jill ^a,c   Chance, Mark R ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Carnegie Mellon University   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e Case Western Reserve University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; ENZYMES; MOLECULAR BIOLOGY;

ANALYSIS FRAMEWORKS; COMBINATORIAL NETWORKS; EXPRESSION DATA; GLIOBLASTOMA MULTIFORME; MOLECULAR BASIS; MOLECULAR PATTERNS; MOLECULAR SIGNATURES; PROTEIN EXPRESSIONS; PROTEIN-PROTEIN INTERACTION NETWORKS; SUBNETWORKS;

GENE EXPRESSION;

DNA METHYLTRANSFERASE 1; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN CANX; PROTEIN HSPA9; PROTEIN KINASE; PROTEIN PSMD3; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MOLECULAR MECHANICS; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REGULATORY MECHANISM; SHORT TERM SURVIVAL; STRUCTURE ANALYSIS;

BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GLIOBLASTOMA; HUMANS; PROTEIN KINASES; PROTEOMICS; SURVIVORS;

EID: 84884685531     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003237     Document Type: Article

References (44)

1. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, et al. (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69: 2091-2099.
2. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, et al. (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65: 4051-4058.
3. Ein-Dor L, Zuk O, Domany E, (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103: 5923-5928.
4. Zhang J, Liu B, Jiang X, Zhao H, Fan M, et al. (2009) A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One 4: e6274.
5. Chowdhury SA, Nibbe RK, Chance MR, Koyuturk M, (2011) Subnetwork state functions define dysregulated subnetworks in cancer. J Comput Biol 18: 263-281.
6. The Cancer Genome Atlas (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
7. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
8. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, et al. (2008) Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 1: 52.
9. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, et al. (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65: 1678-1686.
10. Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, et al. (2006) Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 66: 11502-11513.
11. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, et al. (2004) Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10: 228-233.
12. Venet D, Dumont JE, Detours V, (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7: e1002240.
13. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, et al. (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607.
14. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510.
15. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
16. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, et al. (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4: e7752.
17. Price ND, Trent J, El-Naggar AK, Cogdell D, Taylor E, et al. (2007) Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A 104: 3414-3419.
18. Tao Y, Pinzi V, Bourhis J, Deutsch E, (2007) Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 4: 591-602.
19. Chakravarti A, Loeffler JS, Dyson NJ, (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207.
20. Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD, (2007) Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 145: 795-811.
21. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, et al. (2010) Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54: 921-926.
22. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, et al. (2009) A network model of a cooperative genetic landscape in brain tumors. JAMA 302: 261-275.
23. Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, et al. (2010) Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 1: 265-277.
24. Perego C, Vanoni C, Massari S, Raimondi A, Pola S, et al. (2002) Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J Cell Sci 115: 3331-3340.
25. Rossi M, Magnoni L, Miracco C, Mori E, Tosi P, et al. (2011) beta-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 11: 753-761.
26. Weller M, Winter S, Schmidt C, Esser P, Fontana A, et al. (1997) Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int J Cancer 73: 707-714.
27. Teicher BA, (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271.
28. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
29. Laurent JM, Vogel C, Kwon T, Craig SA, Boutz DR, et al. (2010) Protein abundances are more conserved than mRNA abundances across diverse taxa. Proteomics 10: 4209-4212.
30. Rajcevic U, Petersen K, Knol JC, Loos M, Bougnaud S, et al. (2009) iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics 8: 2595-2612.
31. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
32. Korkolopoulou P, Levidou G, Saetta AA, El-Habr E, Eftichiadis C, et al. (2008) Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 39: 1143-1152.
33. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, et al. (2011) NFKBIA deletion in glioblastomas. N Engl J Med 364: 627-637.
34. Yi X, Luk JM, Lee NP, Peng J, Leng X, et al. (2008) Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 7: 315-325.
35. Dundas SR, Lawrie LC, Rooney PH, Murray GI, (2005) Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 205: 74-81.
36. Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul SC, et al. (1997) Elevated levels of mortalin expression in human brain tumors. Exp Cell Res 237: 38-45.
37. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, et al. (2005) Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24: 344-354.
38. Mani A, Gelmann EP, (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789.
39. Okada Y, Kamatani Y, Takahashi A, Matsuda K, Hosono N, et al. (2010) Common variations in PSMD3-CSF3 and PLCB4 are associated with neutrophil count. Hum Mol Genet 19: 2079-2085.
40. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
41. Iwatsuki K, Kumara E, Yoshimine T, Nakagawa H, Sato M, et al. (2000) Elastase expression by infiltrating neutrophils in gliomas. Neurol Res 22: 465-468.
42. Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, et al. (2010) Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 132: 39-48.
43. Prasad TSK, Kandasamy K, Pandey A, (2009) Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol Biol 577: 67-79.
44. Patel VN, Chance MR (2013) Colorectal Cancer and Its Molecular Subsystems: Construction, Interpretation, and Validation. In: Emmert-Streib F, Dehmer M, editors. Statistical Diagnostics for Cancer: Analyzing High-Dimensional Data. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA.